FDA cites blood cancer risk linked to TNF blockers in young patients

04/14/2011 | Reuters

The FDA cautioned that a drug class called tumor necrosis factor inhibitors has been associated with hepatosplenic T-cell lymphoma, particularly among teens and young adults. A majority of the cases involved patients treated for ulcerative colitis or Crohn's disease. Labels have been updated for Johnson & Johnson's Remicade and Abbott Laboratories' Humira, the FDA said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT